Geode Capital Management LLC Grows Stock Holdings in Insulet Corporation $PODD

Geode Capital Management LLC raised its position in Insulet Corporation (NASDAQ:PODD) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,006,413 shares of the medical instruments supplier’s stock after acquiring an additional 41,019 shares during the quarter. Geode Capital Management LLC’s holdings in Insulet were worth $568,274,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Glenmede Investment Management LP increased its position in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after acquiring an additional 35 shares during the period. Curi Capital LLC increased its position in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares during the period. WINTON GROUP Ltd increased its position in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the period. Camarda Financial Advisors LLC boosted its stake in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC boosted its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on PODD. Citigroup cut their target price on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday. Weiss Ratings lowered shares of Insulet from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. JPMorgan Chase & Co. cut their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Robert W. Baird cut their target price on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $252.04.

Insulet Trading Up 1.6%

Shares of PODD opened at $144.94 on Friday. Insulet Corporation has a 1-year low of $140.63 and a 1-year high of $354.88. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 1.15 and a beta of 1.20. The firm’s 50-day moving average price is $183.55 and its 200-day moving average price is $245.30. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the company posted $1.02 EPS. Insulet’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet Corporation will post 6.44 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.